Share on LinkedInShare on LinkedIn

ARTICLE · 23 DECEMBER 2015

Pharmaceutical Data Protection In Canada: The Latest Word From Photocure

Gowling WLG
Gowling WLG
Contributor
Gowling WLG

Gowling WLG

The firm The firm’s lawyers speak English, French, Russian and Ukrainian. The firm’s client base...

View firm profile
Explore more from Gowling WLG

In the recent Photocure decision the Federal Court has once again sided with Canada's Minister of Health in denying data protection for a new medicinal ingredient.

CanadaIntellectual Property

In the recent Photocure1 decision the Federal Court has once again sided with Canada's Minister of Health in denying data protection for a new medicinal ingredient. In Photocure, the medicinal ingredient was labelled "a variation" of a previously approved medicinal ingredient. While Photocure presented expert evidence to the contrary, the Court refused to consider the evidence, refusing data protection in the process and opening the door to generic copying of Photocure's data filed with its New Drug Submission. This case presents an opportunity to examine the Minister's unbeaten track record in data protection judicial review applications and consider how we arrived at the present state of affairs.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from